Flucytosine is a fluorinated analogue of cytosine. Flucytosine is an orally effective synthetic anti-mycotic agent used for the treatment of systemic fungal infections produced by yeasts. Flucytosine acts mainly against Candida and Cryptococcus and also against some of the species Cladosporium and Phialophora. A new reverse phase liquid chromatographic method has been proposed for the quantification of Flucytosine in pharmaceutical formulations and the method was validated as per ICH guidelines. Mobile phase consisting of a mixture of water: methanol: acetic acid (50:50: 0.1 v/v) with a flow rate 1 mL/min and UV detection at 264 nm was used for the assay of Flucytosine. The drug was exposed to different stress conditions such as acidic, alkaline, oxidation and thermal degradation. Linearity was observed over the concentration range 0.5–120 µg/mL with linear regression equation y = 74185x- 5852.7 (r2 = 0.9999). The LOD was found to be 0.1393 µg/mL and the LOQ was found to be 0.4187 µg/mL. The present method can be applied for the pharmaceutical formulations, kinetics study and bioanalytical studies.
Cite this article:
Kalyani Lingamaneni, Mukthinuthalapati Mathrusri Annapurna. Development and Validation a New Stability Indicating LC method for the Quantification of Flucytosine. Research J. Pharm. and Tech. 2021; 14(1):378-384. doi: 10.5958/0974-360X.2021.00069.X
Kalyani Lingamaneni, Mukthinuthalapati Mathrusri Annapurna. Development and Validation a New Stability Indicating LC method for the Quantification of Flucytosine. Research J. Pharm. and Tech. 2021; 14(1):378-384. doi: 10.5958/0974-360X.2021.00069.X Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-1-69
. David N H. Total Burn Care, 3rd edition, 2007.
. Elias JA, Michael RMcG and Michael AP. Clinical Mycology, 2nd Edition, 2009.
. Frank DBJAM. Pharmacology and Therapeutics for Dentistry, 7th Edition, 2017.
. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. Journal of Antimicrobial Chemotherapy. 2000; 46(2): 171-179.
. Ullrich S, Lisa MN and Joseph G. Improved procedure for determination of Flucytosine in human blood plasma by high-pressure liquid chromatography. Antimicrobial Agents and Chemotherapy. 1984; 26(3): 303-305.
. Serve KM, Yanez JA, Remsberg CM, Davies NM, Black ME. Development and validation of a rapid and sensitive HPLC method for the quantification of 5-fluorocytosine and its metabolites. Biomedical Chromatography. 2010; 24(5): 556 -561.
. Bury RW, Mashford ML and Miles HM. Assay of Flucytosine (5-fluorocytosine) in human plasma by high-pressure liquid chromatography. Antimicrobial Agents and Chemotherapy. 1979; 16(5): 529-532.
. Wade D and Sudlow G. Fluorometric measurement of 5-fluorocytosine in biological fluids. Journal of Pharmaceutical Sciences. 1973; 62(5): 828-829.
. Schiavone DJ, Page MD, Dawborn JK. Rapid microbiological assay for 5-fluorocytosine. Brazilian Medical Journal. 1973; 17(4): 380-382.
. Milind U, Mahesh S, Vilas Ch. A validated stability-indicating HPLC assay method for Flucytosine in bulk drug. International Journal of Innovations in Engineering and Technology. 2017; 8(1):155-161.
. Mathrusri Annapurna M, Rajasree B and Debi Prasad P. New stability indicating RP-UFLC method for the determination of Flucytosine-An anti-fungal Agent. Acta Scientific Pharmaceutical Sciences. 2019; 3(5): 38-46.
. Mohabbat U, Anisur Rahman Md. Development and validation of a Stability indicating RP-HPLC method for determination of Flucytosine and its process related impurities in injectable pharmaceuticals. International Journal of Advances in Pharmaceutical Analysis. 2018; 5(1): 2277-9353.
. ICH Validation of analytical procedures: Text and methodology Q2 (R1), International Conference on Harmonization, 2005.
. ICH Stability testing of new drug substances and products Q1A (R2), International Conference on Harmonization, 2003.